- Home
- BOW vs ARQT Comparison
BOW vs ARQT Comparison
Compare BOW & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BOW
- ARQT
- Stock Information
- Founded
- BOW 2020
- ARQT 2016
- Country
- BOW United States
- ARQT United States
- Employees
- BOW N/A
- ARQT N/A
- Industry
- BOW Property-Casualty Insurers
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- BOW Finance
- ARQT Health Care
- Exchange
- BOW Nasdaq
- ARQT Nasdaq
- Market Cap
- BOW 1.1B
- ARQT 1.1B
- IPO Year
- BOW 2024
- ARQT 2020
- Fundamental
- Price
- BOW $32.97
- ARQT $13.08
- Analyst Decision
- BOW Hold
- ARQT Strong Buy
- Analyst Count
- BOW 5
- ARQT 5
- Target Price
- BOW $33.60
- ARQT $17.00
- AVG Volume (30 Days)
- BOW 95.3K
- ARQT 1.9M
- Earning Date
- BOW 02-15-2025
- ARQT 02-25-2025
- Dividend Yield
- BOW N/A
- ARQT N/A
- EPS Growth
- BOW 130.44
- ARQT N/A
- EPS
- BOW 1.08
- ARQT N/A
- Revenue
- BOW $389,135,000.00
- ARQT $138,708,000.00
- Revenue This Year
- BOW N/A
- ARQT $215.24
- Revenue Next Year
- BOW $26.70
- ARQT $53.63
- P/E Ratio
- BOW $30.70
- ARQT N/A
- Revenue Growth
- BOW 107.43
- ARQT 182.84
- 52 Week Low
- BOW $22.14
- ARQT $5.38
- 52 Week High
- BOW $37.81
- ARQT $16.20
- Technical
- Relative Strength Index (RSI)
- BOW N/A
- ARQT 41.94
- Support Level
- BOW N/A
- ARQT $13.33
- Resistance Level
- BOW N/A
- ARQT $15.09
- Average True Range (ATR)
- BOW 0.00
- ARQT 0.86
- MACD
- BOW 0.00
- ARQT -0.16
- Stochastic Oscillator
- BOW 0.00
- ARQT 6.25
About BOW Bowhead Specialty Holdings Inc. Common Stock
Bowhead Specialty Holdings Inc is engaged in providing specialty P&C products. It is a specialty insurance group that generates revenues by underwriting and offering a variety of specialty insurance products to domestic markets through three distinct underwriting divisions: Casualty, Professional Liability and Healthcare. Casualty specialize in GL coverage for risks in the construction, distribution, heavy manufacturing, real estate and hospitality segments and also consider underwriting risks in a broader range of industries. Key revenue is generated from Casualty segment.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.